Skip Nav Destination
Issues
1 July 2015
-
Cover Image
Cover Image
Disruption of DNA repair capacity is associated with cancer susceptibility, but it remains unclear if the inherent tumor phenotypes of DNA repair deficiency syndromes can be regulated by manipulating DNA repair pathways. BLM is a structure-specific helicase which functions in many aspects of DNA homeostasis. Increasing BLM dosage in vivo in the pink-eyed unstable (pun) mouse model lowers endogenous levels of homologous recombination (HR). Transgenic expression of BLM reduces pigmented eye-spots that spontaneously develop in mouse retinal pigment epithelial (RPE) cells. In pun mice, eye-spots arise because of a characteristic intra-chromosomal, HR-dependent deletion within the mouse p gene which restores melanin production in the otherwise transparent cells of the RPE. Thus, absolute numbers of RPE eye-spots represent an in vivo read-out of HR levels. The cover illustration depicts a clone of (five) pigmented cells in a RPE whole mount, originating from a single reversion event. Brown melanosomes are restricted to the cytoplasm, defining cell nuclei as clear regions. For more information on the effects of transgenic BLM expression on the intestinal tumor burden and pathology of ApcMin/+ mouse models of familial adenomatous polyposis coli, see the article by McIlhatton et al. (beginning on page 650). - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Editorials
Research Articles
Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial
Sarah H. Nash; Jeannette M. Schenk; Alan R. Kristal; Phillis J. Goodman; M. Scott Lucia; Howard L. Parnes; Ian M. Thompson; Scott M. Lippman; Xiaoling Song; Bora Gurel; Angelo De Marzo; Elizabeth A. Platz
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.